

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("6348589").PN.	USPAT	OR	OFF	2006/03/09 11:08
S1	161	536/25.6	US-PGPUB; USPAT	OR	OFF	2006/03/09 11:08
S2	51	536/25.6 and dinucleotide	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:56
S3	2393	424/45	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:37
S4	12	424/45 and dinucleotide	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:39
S5	84	514/851	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:41
S6	435	514/47	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:41
S7	48	514/47 and dinucleotide	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:43
S8	262	514/51	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:43
S9	32	514/51 and dinucleotide	US-PGPUB; USPAT	OR	OFF	2002/09/06 13:43
S10	8	(("4855304") or ("5495550") or ("5635160") or ("5681823") or ("5837861") or ("5900407") or ("6159952") or ("6331529")).PN.	US-PGPUB; USPAT; USOCR	OR	OFF	2002/12/19 10:21
S11	2	09/747777	US-PGPUB; USPAT	OR	OFF	2002/12/19 10:24
S12	1	09/570231	US-PGPUB; USPAT	OR	OFF	2002/12/19 10:24
S13	1	(("9602554") or ("5635160")).PN.	USPAT; USOCR	OR	OFF	2003/08/07 15:06
S14	8	("9602554").PN.	USPAT; USOCR; DERWENT	OR	OFF	2003/08/07 15:12
S15	2	(excipient and osmolarity) and dinucleotide	USPAT	OR	OFF	2003/08/07 15:13
S16	246	excipient and osmolarity	USPAT	OR	OFF	2003/08/07 15:16

EAST Search History

S17	47	((("6596725") or ("6331523") or ("5948801") or ("6372753") or ("6124259") or ("6475508") or ("6462071") or ("5767079") or ("6114320") or ("5665769") or ("5722428") or ("5181922") or ("5366474") or ("5596011") or ("6075032") or ("5423800") or ("5688264") or ("6451763") or ("6573271") or ("6384081") or ("5743274") or ("5824073") or ("6059828") or ("6059828") or ("6126687") or ("6217594") or ("6217594") or ("5037384") or ("6149931") or ("5824685") or ("5941250") or ("6156042") or ("6159218") or ("6162242") or ("6524330") or ("6622729") or ("5336175") or ("5817075") or ("6378526") or ("6397849") or ("6540391") or ("6284245") or ("5527356") or ("6696415") or ("5641750") or ("5736516") or ("5286261") or ("6640124") or ("6071924") or ("4299227).pn")). PN.	USPAT; USOCR	OR	OFF	2004/03/12 10:26
S18	47	((("6596725") or ("6331523") or ("5948801") or ("6372753") or ("6124259") or ("6475508") or ("6462071") or ("5767079") or ("6114320") or ("5665769") or ("5722428") or ("5181922") or ("5366474") or ("5596011") or ("6075032") or ("5423800") or ("5688264") or ("6451763") or ("6573271") or ("6384081") or ("5743274") or ("5824073") or ("6059828") or ("6059828") or ("6126687") or ("6217594") or ("6217594") or ("5037384") or ("6149931") or ("5824685") or ("5941250") or ("6156042") or ("6159218") or ("6162242") or ("6524330") or ("6622729") or ("5336175") or ("5817075") or ("6378526") or ("6397849") or ("6540391") or ("6284245") or ("5527356") or ("6696415") or ("5641750") or ("5736516") or ("5286261") or ("6640124") or ("6071924") or ("4299227).pn")). PN.	USPAT; USOCR	OR	OFF	2004/07/08 12:53


EAST Search History

S19	5045	dinucleotide and composition	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:56
S20	10567	514/12	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:56
S21	191	514/12 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:57
S22	1254	514/277	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:57
S23	10	514/277 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:57
S24	1096	424/427	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:57
S25	3	424/427 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S26	6826	128/898	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:57
S27	15	128/898 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S28	245	623/4.1	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S29	0	623/4.1 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S30	1200	606/107	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S31	3	606/107 and (dinucleotide and composition)	US-PGPUB; USPAT	OR	OFF	2004/07/08 12:58
S32	7	("6555675") or ("6319908") or ("6548658") or ("6596725") or ("6673779") or ("6696425") or ("6348589")).PN.	USPAT	OR	OFF	2005/10/14 09:52
S33	2	("6040297") or ("6458946")).PN.	USPAT	OR	OFF	2005/10/14 11:03
S34	1	("6818629").PN.	USPAT	OR	OFF	2005/10/14 11:03
S35	1	("5248699").PN.	USPAT	OR	OFF	2005/10/14 13:48


L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 211448-85-0 REGISTRY
 CN Uridine 5'-(pentahydrogen tetraphosphate), P¹'→5'-ester with
 2'-deoxycytidine (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Denufosol
 FS STEREOSEARCH
 MF C18 H27 N5 O21 P4
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, PROUSDDR,
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); RACT (Reactant or reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 USES (Uses)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 14264-46-1 REGISTRY
CN Uridine 5'-(tetrahydrogen triphosphate), tetrasodium salt (8CI, 9CI) (CA
INDEX NAME)
OTHER NAMES:
CN Sodium UTP
CN Uridine triphosphate sodium salt
FS STEREOSEARCH
MF C9 H15 N2 O15 P3 . 4 Na
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER,
USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
CRN (63-39-8)

Absolute stereochemistry.



● 4 Na

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ibib abs 1-7

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:348995 CAPLUS
DOCUMENT NUMBER: 142:367712
TITLE: Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
INVENTOR(S): Yerxa, Benjamin R.; Peterson, Ward M.; Rideout, Janet L.; Pendergast, William
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S.
Ser. No. 397,795.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005085439	A1	20050421	US 2004-962016	20041007
US 5837861	A	19981117	US 1997-798508	19970210
WO 9834942	A2	19980813	WO 1998-US2702	19980206
WO 9834942	A3	20000106		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW		
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
US 6348589	B1	20020219	US 1998-101395	19980710
US 2001031743	A1	20011018	US 2001-774752	20010130
US 6596725	B2	20030722		
US 2003186917	A1	20031002	US 2003-397795	20030325
US 6818629	B2	20041116		
PRIORITY APPLN. INFO.:			US 1997-798508	A2 19970210
			WO 1998-US2702	W 19980206
			US 1998-101395	A2 19980710
			US 2001-774752	A2 20010130
			US 2003-397795	A2 20030325
			US 1997-797472	A2 19970206

AB The invention provides a method of treating edematous **retinal** disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathol. extraneous fluid from the subretinal and **retinal** spaces and thereby reduce the accumulation of said fluid associated with **retinal** detachment and **retinal** edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous **retinal** disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compds., or hydrolysis-resistant mononucleoside triphosphate salts. The invention also provides P1-(2'-deoxycytidine 5')-P4-(uridine 5')-tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetrolithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The invention further provides a pharmaceutical formulation comprising a P1-(2'-deoxycytidine 5')-P4-(uridine 5')-tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:777379 CAPLUS
DOCUMENT NUMBER: 139:286382
TITLE: Method for the treatment of edematous **retinal** disorders
INVENTOR(S): Peterson, Ward M.; Yerxa, Benjamin R.

PATENT ASSIGNEE(S) : Inspire Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S.
 Ser. No. 774,752.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 18
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003186917	A1	20031002	US 2003-397795	20030325
US 6818629	B2	20041116		
US 5837861	A	19981117	US 1997-798508	19970210
WO 9834942	A2	19980813	WO 1998-US2702	19980206
WO 9834942	A3	20000106		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6348589	B1	20020219	US 1998-101395	19980710
US 2001031743	A1	20011018	US 2001-774752	20010130
US 6596725	B2	20030722		
US 2005085439	A1	20050421	US 2004-962016	20041007
PRIORITY APPLN. INFO.:			US 1997-798508	W 19970210
			WO 1998-US2702	W 19980206
			US 1998-101395	A2 19980710
			US 2001-774752	A2 20010130
			US 1997-797472	A2 19970206
			US 2003-397795	A2 20030325

OTHER SOURCE(S) : MARPAT 139:286382

AB The invention provides method for the treatment of edematous **retinal** disorders. Method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathol. extraneous fluid from the subretinal and **retinal** spaces and thereby reduce the accumulation of said fluid associated with **retinal** detachment and **retinal** edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous **retinal** disorders. The pharmaceutical formulation useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compds., or hydrolysis-resistant mononucleoside triphosphates.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:136070 CAPLUS
 DOCUMENT NUMBER: 136:151393
 TITLE: Preparation of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
 INVENTOR(S): Pendergast, William; Yerxa, Benjamin R.; Rideout, Janet L.; Siddiqi, Suhaib M.
 PATENT ASSIGNEE(S) : Inspire Pharmaceuticals, Inc., USA
 SOURCE: U.S., 15 pp., Cont.-in-part of U.S. 5,900,407.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 18
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 6348589	B1	20020219	US 1998-101395	19980710
US 5900407	A	19990504	US 1997-797472	19970206
US 5837861	A	19981117	US 1997-798508	19970210
WO 9834942	A2	19980813	WO 1998-US2702	19980206
WO 9834942	A3	20000106		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 2002082417	A1	20020627	US 2001-7451	20011106
US 6977246	B2	20051220		
US 2003186917	A1	20031002	US 2003-397795	20030325
US 6818629	B2	20041116		
US 2004077585	A1	20040422	US 2003-682545	20031008
JP 2005015491	A2	20050120	JP 2004-265998	20040913
US 2005085439	A1	20050421	US 2004-962016	20041007
PRIORITY APPLN. INFO.:				
US 1997-797472 A2 19970206				
US 1997-798508 A2 19970210				
WO 1998-US2702 W 19980206				
JP 1998-535054 A3 19980206				
US 1998-101395 A1 19980710				
US 1999-397795 A3 19990917				
US 2001-774752 A2 20010130				
US 2003-397795 A2 20030325				

OTHER SOURCE(S) : MARPAT 136:151393

GI



AB The present invention relates to certain novel dinucleotides I ($X = O$, CH_2 , imido, CF_2 ; B , $B1$ = independently nucleobase; Z , $Z1$ = independently OH , $N3$; Y , $Y1$ = independently H , OH ; $Q = (HPO_3)m$; $n = 0-2$; $m = 0-2$; $n + m = 0-4$) and formulations thereof which are highly selective agonists of the P2Y2 and/or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compds. of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and **retinal** detachment. Thus, P1,P2-di(uridine-5')-P2,P3-methylenetetraphosphate was prepared as P2Y2 and/or P2Y4 purinergic receptor ($EC_{50} = 11.1 \mu\text{mol}$).

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:851183 CAPLUS

DOCUMENT NUMBER: 136:690

TITLE: Method for **retinal** degeneration treatment with purinergic receptor agonists

INVENTOR(S): Peterson, Ward M.

PATENT ASSIGNEE(S): Inspire Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087913	A2	20011122	WO 2001-US15606	20010510
WO 2001087913	A3	20020530		
WO 2001087913	C2	20030320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6864243	B1	20050308	US 2000-570231	20000512
CA 2408842	AA	20011122	CA 2001-2408842	20010510
EP 1280536	A2	20030205	EP 2001-933343	20010510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001010418	A	20030408	BR 2001-10418	20010510
JP 2003533536	T2	20031111	JP 2001-584306	20010510
US 2005009778	A1	20050113	US 2004-916086	20040810
PRIORITY APPLN. INFO.:			US 2000-570231	A 20000512
			WO 2001-US15606	W 20010510

OTHER SOURCE(S): MARPAT 136:690

AB Methods are disclosed for prevention or treatment of **retinal** degeneration arising from pathophysiol. or phys. conditions. The method involves administration of a pharmaceutical composition comprising a purinergic P2Y receptor ligand, in an amount effective to elevate its extracellular concentration to activate **retinal** glial and neuronal cell surface P2Y receptors and mount a neuroprotective response. Also disclosed are methods of administration including intravitreal bolus and sustained-release administration, transscleral delivery, topical, and systemic administration. The pharmaceutical composition useful in the invention comprises a P2Y purinergic receptor agonist, which include uridine 5'-di -and triphosphate (UDP, UTP) and their analogs, ADP (ADP) and its analogs, cytidine 5'-di- and triphosphate (CDP, CTP) and their analogs, and dinucleoside polyphosphate compds.

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:763523 CAPLUS
DOCUMENT NUMBER: 135:298823
TITLE: Use of P2Y receptor agonist dinucleotide compounds to stimulate removal of fluid in **retinal** detachment and **retinal** edema
INVENTOR(S): Peterson, Ward M.; Yerxa, Benjamin R.
PATENT ASSIGNEE(S): Peterson, Ward M., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. 5,837,861.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001031743	A1	20011018	US 2001-774752	20010130
US 6596725	B2	20030722		
US 5837861	A	19981117	US 1997-798508	19970210
ZA 9801073	A	19990219	ZA 1998-1073	19980210
US 2002103158	A1	20020801	US 2001-817017	20010323
US 6555675	B2	20030429		

CA 2436429	AA	20020808	CA 2002-2436429	20020129
WO 2002060454	A2	20020808	WO 2002-US3934	20020129
WO 2002060454	A3	20021227		
WO 2002060454	B1	20030213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1355652	A2	20031029	EP 2002-714865	20020129
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005503325	T2	20050203	JP 2002-560646	20020129
BR 2002006693	A	20050503	BR 2002-6693	20020129
US 2003186917	A1	20031002	US 2003-397795	20030325
US 6818629	B2	20041116		
US 2004077585	A1	20040422	US 2003-682545	20031008
US 2005085439	A1	20050421	US 2004-962016	20041007
PRIORITY APPLN. INFO.:				
US 1997-798508 A2 19970210				
WO 1998-US2702 W 19980206				
US 1998-101395 A2 19980710				
US 1999-397795 A3 19990917				
US 2001-774752 A2 20010130				
US 2001-817017 A 20010323				
WO 2002-US3934 W 20020129				
US 2003-397795 A2 20030325				

OTHER SOURCE(S): MARPAT 135:298823

AB The invention provides a method of treating edematous **retinal** disorders. The method comprises administration of a P2Y receptor agonist to stimulate the removal of pathol. extraneous fluid from the subretinal and **retinal** spaces and thereby reduce the accumulation of said fluid associated with **retinal** detachment and **retinal** edema. The P2Y receptor agonist may be administered with therapeutic and adjuvant agents commonly used to treat edematous **retinal** disorders. The pharmaceutical composition useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compds.

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:335023 CAPLUS
 DOCUMENT NUMBER: 132:339428
 TITLE: Defined serum-free medical solution for ophthalmology
 INVENTOR(S): Skelnik, Debra A.
 PATENT ASSIGNEE(S): Bausch and Lomb Surgical, Inc., USA
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1000541	A1	20000517	EP 1999-308702	19991102
EP 1000541	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6153582	A	20001128	US 1998-186580	19981105
AU 9957108	A1	20000511	AU 1999-57108	19991028
AU 769082	B2	20040115		
JP 2000198701	A2	20000718	JP 1999-313063	19991102
AT 257648	E	20040115	AT 1999-308702	19991102
PT 1000541	T	20040831	PT 1999-308702	19991102
ES 2217700	T3	20041101	ES 1999-308702	19991102

PRIORITY APPLN. INFO.:

US 1998-186580 A 19981105

AB The title solution contains one or more cell nutrient supplements and a growth factor which maintains and enhances the preservation of eye tissues, including human corneal, **retinal**, and corneal epithelial tissues at low to physiol. temperature (2-38°). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with glycosaminoglycans, deturgescents agents, energy sources, buffer systems, antioxidants, membrane stabilizers, antibiotics, antimycotics, ATP or energy precursors, nutrient cell supplements, nonessential amino acids, trace minerals, trace elements, and growth factors.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:550430 CAPLUS

DOCUMENT NUMBER: 129:175919

TITLE: Preparation of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency

INVENTOR(S): Pendergast, William; Yerxa, Benjamin R.; Rideout, Janet L.; Siddiqi, Suhaib M.

PATENT ASSIGNEE(S): Inspire Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 18


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834942	A2	19980813	WO 1998-US2702	19980206
WO 9834942	A3	20000106		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5900407	A	19990504	US 1997-797472	19970206
US 5837861	A	19981117	US 1997-798508	19970210
CA 2279963	AA	19980813	CA 1998-2279963	19980206
AU 9863242	A1	19980826	AU 1998-63242	19980206
AU 738907	B2	20010927		
EP 981534	A2	20000301	EP 1998-907435	19980206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9807169	A	20000606	BR 1998-7169	19980206
JP 2001526635	T2	20011218	JP 1998-535055	19980206
NZ 337225	A	20020328	NZ 1998-337225	19980206
US 6348589	B1	20020219	US 1998-101395	19980710
NO 9903776	A	19991006	NO 1999-3776	19990804
US 2002082417	A1	20020627	US 2001-7451	20011106
US 6977246	B2	20051220		
US 2003036527	A1	20030220	US 2002-163804	20020605
US 6673779	B2	20040106		
US 2003186917	A1	20031002	US 2003-397795	20030325
US 6818629	B2	20041116		
US 2004077585	A1	20040422	US 2003-682545	20031008
JP 2005015491	A2	20050120	JP 2004-265998	20040913
US 2005085439	A1	20050421	US 2004-962016	20041007
PRIORITY APPLN. INFO.:			US 1997-797472	A2 19970206
			US 1997-798508	A2 19970210
			JP 1998-535054	A3 19980206
			WO 1998-US2702	W 19980206
			US 1998-101395	A1 19980710

US 1998-101840	A2 19980717
US 1999-397795	A3 19990917
US 2001-774752	A2 20010130
US 2001-7451	A2 20011106
US 2003-397795	A2 20030325

OTHER SOURCE(S) :
GI

MARPAT 129:175919



AB The present invention relates to certain novel dinucleotides I ($X = O, CH_2, imido, CF_2$; $B, B1 = independently nucleobase; Z, Z1 = independently OH, N_3; Y, Y1 = independently H, OH; Q = (HPO_3)m; n = 0-2; m = 0-2; n + m = 0-4$) and formulations thereof which are highly selective agonists of the P2Y2 and/or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compds. of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and **retinal** detachment. Thus, P1,P2-di(uridine-5')-P2,P3-methylenetetraphosphate was prepared as P2Y2 and/or P2Y4 purinergic receptor ($EC_{50} = 11.1 \mu\text{mol}$).